Table 3.

Characteristics of treatment-refractory patients

	Sex	Age at onset	Antibody	Thymectomy	Histology	Time to refractory MG (mos.)	IS treatment at refractory timepoint	MGFA class at last FU
1	m	73	AChR	No	NA	60	CS 5 mg, MMF 1000 mg, CP (1g4w)	IIIa
2	m	59	AChR	No	NA	56	CS 75 mg, CP (1 g q4w), IA/PLEX	IIIb
3	m	41	MuSK	No	NA	24	CS 18.8 mg, TC 6 mg, IA/PLEX	IIb
4	m	54	AChR	Yes	Thymoma	24	CS 12.5 mg, AZA 150 mg, IA/PLEX	0 (MM3)
5	f	22	SN	Yes	Hyperplasia	197	CS 10 mg, RTX (375 mg/m2 BSA)	IIa
6	f	35	AChR	Yes	Thymoma	74	CS 25 mg, MMF 2000 mg	IIa
7	f	27	AChR	Yes	Normal	24	CS 8.75 mg, AZA 150 mg, IA/PLEX	IIb
8	m	13	AChR	Yes	Hyperplasia	158	MMF 150, RTX (375 mg/m2 BSA), IA/PLEX	I
9	m	49	AChR	No	NA	52	CS 25 mg, AZA 200 mg, IVIG	I
10	m	28	SN	Yes	Hyperplasia	49	CS 25 mg, MMF 2000 mg, IVIG	I
11	f	27	AChR	Yes	Normal	24	CS 25 mg, AZA 100 mg, IVIG	IIb
12	m	48	AChR	Yes	Thymoma	25	CS 17.5 mg, MMF 2000 mg, RTX (375 mg/m2 BSA), IVIG	IIa
13	f	31	SN	Yes	Normal	25	CS 20 mg, AZA 100 mg, RTX (375 mg/m2 BSA); IA/PLEX	IIIa
14	f	20	AChR	Yes	Hyperplasia	40	CS 12.5 mg, AZA 100 mg	IIIb

Characteristics of treatment-refractory patients. Treatment is shown for the timepoint patients met the definition of refractory MG

AChR denotes acetylcholine receptor, AZA azathioprine, BSA body surface area, CP Cyclophosphamide, CS corticosteroids, FU follow-up, IA/PLEX immunoadsorption or plasma exchange therapy (maintenance treatment), IS immunosuppressive, IVIG intravenous immunoglobulins (maintenance treatment), MG myasthenia gravis, MGFA Myasthenia Gravis Foundation of America, MM minimal manifestation, MMF mycophenolate mofetil, MuSK muscle-specific receptor tyrosine kinase, NA not applicable, SN seronegative, TC tacrolimus